2[4]Gerd A,FRCP,Rafael,et al.Coronary heart disease:reducing the risk a worldwide view[J].Circulation,1999,100:1930-1938.
3[5]Scott MG,Richard P,Philip G,et al.Assessment of cardiovascular risk by use of multiple-risk-factor assessment equation:a statement for healthcare professionals from the american heart association and the american college of cardiology[J].J Am Coll Cardiol,1999,34:1348-1359.
4[6]Scott MG,Terry B,James C,et al.Beyond secondary prevention:identifying the high-risk patients for primary prevention:medical office association:writing group I[J].Circulation,2000,4:E3-E11.
5[8]Joint European Societies.Recommendations on prevention of coronary heart disease in clinical practice[J].Atherosclerosis,1998,140:199-270.
6[11]Hansson L,Zanchetti A,Carruthers SG,et al.Effects of intensive blood pressure lowering and low-dose aspirin in patients with hypertensives:principal results of the Hypertensives Optimal Trement (HOT) randomized trial[J].Lancet,1998,351:1755-1762.
7[12]Guidelines Subcommittee.1999 World Health Organization-Internation Society of Hypertension guidelines for the management of hypertension[J].J Hypertens,1999,17:151-183.
8[1]Braunwald E, Antman EM, Beasley JW. ACC/AHA guidelines for the ranagement of patient with unstable angina and non ST segment elevation myocardial infarction:a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patient with Unstable Angina)[J ]. J Am Coll Cardiol, 2000,36: 970 - 1062
9[3]The Scandinavian Simvastatin Surrival Study Group.Randomized trial of cholesterol lowering in 4 444 patients with coronary heart disease: the Scandinavian Simvastatin Surrival Study (4s) [ J ]. Lancet, 1994,344:1383 - 1389
10[4]Ridket PM, Rifai N, Pfeffer MA, et al. Inflammation,pravastatin,and the risk of coronary events after myocardial infarction in patients with average cholesteterol levels. Cholesterol and Recurrent Events(CARE)Investigators[ J ]. Circulation, 1998,98: 839 - 844
